{"id":917072,"date":"2026-07-06T20:39:20","date_gmt":"2026-07-06T20:39:20","guid":{"rendered":"https:\/\/www.europesays.com\/us\/917072\/"},"modified":"2026-07-06T20:39:20","modified_gmt":"2026-07-06T20:39:20","slug":"fda-approvals-outrun-staff-cuts-23-novel-drugs-mark-the-best-first-half-in-three-years-endpoints-news","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/917072\/","title":{"rendered":"FDA approvals outrun staff cuts: 23 novel drugs mark the best first half in three years – Endpoints News"},"content":{"rendered":"
    \n
  1. FDA approvals outrun staff cuts: 23 novel drugs mark the best first half in three years<\/a>  Endpoints News<\/li>\n
  2. FDA authorizes more devices so far in 2026, but it\u2019s taking longer<\/a>  MedTech Dive<\/li>\n
  3. Regulatory Actions for June 2026<\/a>  PharmTech.com<\/li>\n
  4. The June 2026 Shift: US FDA Approvals Redefining Global Standards<\/a>  drugscontrol.org<\/li>\n
  5. Despite chaos and churn, FDA decisions hold mostly steady in H1 2026<\/a>  BioSpace<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"FDA approvals outrun staff cuts: 23 novel drugs mark the best first half in three years  Endpoints News FDA…\n","protected":false},"author":3,"featured_media":917073,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[370459,370454,370451,370458,151,370450,210,15817,1060,370453,370456,370455,370461,370449,44350,370457,370452,370460,67,132,68],"class_list":["post-917072","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-bristol-myers-squibb-iberdomide","tag-cnpv","tag-drug-approvals","tag-eli-lilly-obesity-pill","tag-fda","tag-fda-drug-approvals","tag-health","tag-marty-makary","tag-medication","tag-moderna-flu-vaccine","tag-national-priority-voucher-program","tag-novel-drug-applications","tag-novel-drug-approvals-2025","tag-pdufa","tag-pharma","tag-regeneron-gene-therapy","tag-trump-administration-fda","tag-ultragenyx-gene-therapy","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116874966825253183","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/917072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=917072"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/917072\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/917073"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=917072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=917072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=917072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}